AlloVir, Inc. (NASDAQ:ALVR - Get Free Report) was the recipient of a significant decrease in short interest in December. As of December 15th, there was short interest totalling 1,690,000 shares, a decrease of 12.0% from the November 30th total of 1,920,000 shares. Based on an average daily trading volume, of 354,200 shares, the short-interest ratio is currently 4.8 days.
AlloVir Trading Down 3.4 %
ALVR stock traded down $0.02 during mid-day trading on Friday, hitting $0.46. The stock had a trading volume of 167,042 shares, compared to its average volume of 589,223. The firm has a fifty day simple moving average of $0.62 and a 200 day simple moving average of $0.72. The firm has a market capitalization of $52.81 million, a P/E ratio of -0.52 and a beta of 0.59. AlloVir has a 52 week low of $0.40 and a 52 week high of $1.05.
AlloVir (NASDAQ:ALVR - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.10.
Hedge Funds Weigh In On AlloVir
A hedge fund recently bought a new stake in AlloVir stock. Point72 Asia Singapore Pte. Ltd. acquired a new stake in AlloVir, Inc. (NASDAQ:ALVR - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 76,278 shares of the company's stock, valued at approximately $55,000. Point72 Asia Singapore Pte. Ltd. owned approximately 0.07% of AlloVir as of its most recent SEC filing. Institutional investors own 66.05% of the company's stock.
About AlloVir
(
Get Free Report)
Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.
Featured Stories
Before you consider AlloVir, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AlloVir wasn't on the list.
While AlloVir currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
